Formulation and Evaluation of Dispersible Tablet of Furosemide for Pediatric Use

Authors: O. Benaziz, A. Dorbane, S. Djeraba

Abstract:

The objective of this work is to formulate a dry dispersible form of furosemide in the context of pediatric dose adjustment. To achieve this, we have produced a set of formulas that will be tested in process and after compression. The formula with the best results will be improved to optimize the final shape of the product. Furosemide is the most widely used pediatric diuretic because of its low toxicity. The manufacturing process was chosen taking into account all the data relating to the active ingredient and the excipients used and complying with the specifications and requirements of dispersible tablets. The process used to prepare these tablets was wet granulation. Different excipients were used: lactose, maize starch, magnesium stearate and two superdisintegrants. The mode of incorporation of super-disintegrant changes with each formula. The use of super-disintegrant in the formula allowed optimization of the disintegration time. Prepared tablets were evaluated for weight, content uniformity, hardness, disintegration time, friability and in vitro dissolution test. 

Keywords: Formulation, dispersible tablets, wet granulation, superdisintegrants, disintegration.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1316033

References:

[1] Felipe L Lopez, Terry B Ernest, Catherine Tuleu, Mine Orlu Gul, Formulation approaches to pediatric oral drug delivery: benefits and limitations of currents platforms.
[2] D. Brasseur, De meilleurs médicaments pour les enfants Better Medicines for Children. Rev Med Brux 2006.
[3] Statistics produced in the pediatric ward at the University Hospital Center of Beni Messous in Algiers between 2012 and 2014.
[4] Buck J, Huwyler J, Kühl P, Dischinger A, Pediatric dispersible tablets: A modular approach for rapid prototyping.
[5] Marta Slavkova, J. Breitkreutz. Orodispersible drug formulations for children and elderly. European Journal of Pharmaceutical of sciences. 2015
[6] Luana Perioli, G.D.Alba , C.Pagano. A new oral solid dosage form for furosemide oral administration. European Journal of Pharmaceutics and Biopharmaceutics 80 (2012) 621-629.
[7] Volker Bohler. Polyvinylpyrrolidone excipients for pharmaceuticals: povidone, crospovidone, and copovidone.
[8] Julia Krause and J. Breitkreutz. Improving drug delivery in pediatric medicine. Institue of pharmaceutics and biopharmaceutics, Dusseldorf Germany.
[9] Malahah Binti Mohamed. Pharmaceutical applications of Crospovidone. International journal of drug formulation and research. volume 3 Issue 1, Jan- Feb. 2012.
[10] P.S Mohanachandran, P.G Sindhumol, T.S Kiran. Superdisinterants: An overview. Department of Pharmaceutics, Nirmala College of Pharmacy, Muvattupuzha, Kerala, India. Volume 6, Issue 1, January-February 2011; Article-022.
[11] European pharmacopoeia-8th Edition published 15 July 2013.